Biological
2019-nCoV Vaccine mRNA-1273 clinical trials
Also written mRNA-1273.
- studies test it
- 42
- open now
- 3
- in phase 3
- 14
- first study started
- 2020
Keep track of what changes. Save the 2019-nCoV Vaccine mRNA-1273 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Other names
Studies by the year they started
42 studies that test it; most in 2021 (24)
| Year | Studies |
|---|---|
| 2020 | 4 |
| 2021 | 24 |
| 2022 | 8 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 18
- Phase 3
- 14
- Phase 4
- 8
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- COVID-19
- 25
Who runs them
Industry 14 · Other 28
ModernaTX, Inc. (12) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · Murdoch Childrens Research Institute (3) · University Medical Center Groningen (2) · Assistance Publique - Hôpitaux de Paris (2) · Sheba Medical Center (1) · Tor Biering-Sørensen (1) · Merck Sharp & Dohme LLC (1)
Often tested with
Tested in the same studies.
BNT162 Vaccine (12) · MRNA-1283 (3) · Elasomeran/Davesomeran (3) · mRNA-1010 influenza vaccine (2) · mRNA-1273.214 COVID-19 vaccine (2) · Ad26COVS1 (2) · ChAdOx1 nCoV-19 (2) · mRNA-1345 respiratory syncytial virus vaccine (1)
Studies
Open first, then newest update. How each study uses 2019-nCoV Vaccine mRNA-1273 is read from its arms, and is right about nine times in ten.
Testing it · 42
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsNot yet recruitingPhase 4ModernaTX, Inc.NCT07863635Written as mRNA-1273
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsRecruitingPhase 4ModernaTX, Inc.NCT06585241Written as mRNA-1273 Variant-containing Formulation
- Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.RecruitingPhase 4Well- Konnect Healthcare Services and Research FirmNCT06441955Written as Moderna COVID-19 Vaccine
- Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19CompletedPhase 4Tor Biering-SørensenNCT07279766Written as mRNA-1273 (Moderna COVID-19 vaccine)
- A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Active, not recruitingPhase 4ModernaTX, Inc.NCT07266558Written as mRNA-1273
- COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05000216Written as Moderna mRNA-1273
- A Study of Modified mRNA Vaccines in Healthy AdultsCompletedPhase 1ModernaTX, Inc.NCT05397223Written as mRNA-1273
- Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)CompletedPhase 3Merck Sharp & Dohme LLCNCT05119855Written as mRNA-1273 Vaccine
- COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05289037Written as mRNA-1273
- A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19CompletedPhase 2/3ModernaTX, Inc.NCT04649151Written as mRNA-1273
- COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 VaccinationsCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04761822Written as Moderna COVID-19 Vaccine
- COVID-19 Protection After Transplant Pilot StudyCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04969263Written as mRNA-1273 vaccine (Moderna)
- Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to VaccinationWithdrawnPhase 2Maria Joyera RodríguezNCT04930770Written as MRNA-1273
- A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of AgeCompletedPhase 2/3ModernaTX, Inc.NCT04796896Written as mRNA-1273
- Assessing Immune Response of Different COVID-19 Vaccines in Older AdultsCompletedPhase 2Oliver Cornely, MDNCT05160766Written as Spikevax (mRNA-1273)
- Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA VaccinesCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT04889209Written as mRNA-1273
- High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant RecipientsTerminatedPhase 1/2University of California, Los AngelesNCT05280158Written as mRNA-1273 (Moderna COVID-19 vaccine)
- A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) VariantsCompletedPhase 2/3ModernaTX, Inc.NCT04927065Written as mRNA-1273.211
- Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).TerminatedPhase 3Murdoch Childrens Research InstituteNCT05228730Written as Elasomeran - standard dose
- A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor TherapyCompletedPhase 2National Cancer Institute (NCI)NCT04847050Written as Messenger ribonucleic acid (mRNA)-1273 Vaccine
See all 42 studies that test 2019-nCoV Vaccine mRNA-1273 →
Given in every arm · 5 — 2019-nCoV Vaccine mRNA-1273 is usual care beside what is tested
- Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical TrialActive, not recruitingPhase 3Monash UniversityNCT05556720Written as Moderna Bivalent mRNA vaccine
- Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)CompletedPhase 3Merck Sharp & Dohme LLCNCT05158140Written as mRNA-1273
- Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)CompletedPhase 4Novartis PharmaceuticalsNCT04792567Written as mRNA-1273
- A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster VaccineCompletedPhase 3GlaxoSmithKlineNCT05047770Written as mRNA-1273
- Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 VaccineStatus unknownPhase 2Leiden University Medical CenterNCT05315362Written as mRNA-1273
As the comparator · 8 — what is tested is compared with 2019-nCoV Vaccine mRNA-1273
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgeNot yet recruitingPhase 2ModernaTX, Inc.NCT07808697Written as mRNA-1273
- Effectiveness of An Influenza/COVID-19 Vaccine (mCombriax [mRNA-1083]) in Adults ≥ 65 YearsNot yet recruitingPhase 4Tor Biering-SørensenNCT07790523Written as Efluelda® (TIV-HD) and Spikevax® (mRNA-1273)
- A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine BoostersCompletedPhase 2ModernaTX, Inc.NCT05137236Written as mRNA-1273
- Mix and Match of the COVID-19 Vaccine for Safety and ImmunogenicityActive, not recruitingPhase 2Canadian Immunization Research NetworkNCT04894435Written as mRNA-1273 SARS-CoV-2 vaccine
- A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19CompletedPhase 2/3ModernaTX, Inc.NCT05249829Written as mRNA-1273
- Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in AdultsCompletedPhase 2Sheba Medical CenterNCT05383560Written as MRNA-1273 Vaccine
- A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 YearsStatus unknownPhase 2Sinocelltech Ltd.NCT05345873Written as mRNA-1273
- Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant RecipientsStatus unknownPhase 2Medical University of ViennaNCT05324319Written as mRNA-1273
Codes
What other systems call 2019-nCoV Vaccine mRNA-1273 · ClinicalTrials.gg INT006858
- MeSH (NLM) D0000909832019-nCoV Vaccine mRNA-1273Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) EPK39PL4R4ELASOMERANConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000090983 | 2019-nCoV Vaccine mRNA-1273 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | EPK39PL4R4 | ELASOMERAN | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.